-+ 0.00%
-+ 0.00%
-+ 0.00%

Mega Lifesciences Shares Rose Even As Sales Fell

Simply Wall St·11/16/2026 04:33:23
Listen to the news

If you followed Mega Lifesciences this year, the story likely seemed to pivot on one line in its November filing. Revenue for Q3 2026 was THB 3,764.133 million while net income excluding extra items reached THB 615.333 million, and net margin moved to 16.3%. Holding Mega Lifesciences over the past year would have returned 26.1%, including dividends. If you were deciding back on 13 November 2025, what had to be true about expansion, regulation and product relevance for that result to feel reasonable?

Mega Lifesciences has already moved. See which of 201 high quality undervalued stocks still trade below our estimates.

The Two Stories Investors Were Choosing Between On Mega Lifesciences

The shares cost THB29.25 at the start of the period, and Mega Lifesciences sat between two very different stories about where the business might head next.

On the optimistic side, the June 2025 narrative saw a Fair Value of THB32.08. This price was implied by expectations that expansion in Indonesia and Vietnam, plus 3.3% annual revenue growth assumptions and a 16.1% future profit margin, would reward new plants and a broader wellness pipeline.

The July 2025 bear case pinned Fair Value at THB26. This level was tied to concerns that rising regulatory scrutiny in markets such as Myanmar and Indonesia, earnings volatility from FX swings, and pressure on traditional OTC and nutraceutical products could offset margin improvement assumptions and leave the stock exposed to shrinking relevance.

SET:MEGA 1-Year Stock Price Chart
SET:MEGA 1-Year Stock Price Chart

What The Results Changed For Mega Lifesciences

The clearest signal in the period was profitability. Mega Lifesciences reported Q3 2026 revenue of THB 3,764.133 million compared with THB 3,887.301 million in Q3 2025. Net income excluding extra items rose from THB 494.188 million to THB 615.333 million, and net margin widened from 12.7% to 16.3%. That mix of softer revenue but stronger earnings supported parts of both the optimistic and cautious cases, so it cut both ways.

The lesson is that when a story hinges on expansion and regulation, it is useful to test it first through margins and not just sales. For another healthcare stock, track whether net income and margin move in line with any stated efficiency or resilience goals once new capacity and compliance costs start showing in reported results.

What Mega Lifesciences' Recent Run Now Asks You To Believe

Today Mega Lifesciences trades at THB36.75 after a 26.1% gain over the past year. The analyst consensus Narrative on Simply Wall St places its Fair Value above that level, anchored on brand mix, capacity build out and wider reach in emerging markets.

This Narrative argues the current price still does not fully credit successful execution on higher margin branded products and new manufacturing capacity translating into the targeted business mix and profit profile. That is the assumption any buyer at today’s level needs to weigh.

"The current valuation implies the market is still cautious about Mega Lifesciences fully delivering on its plan to roughly double branded business and materially increase bottom line by 2030. This underpins the view that the stock may be undervalued and that investors with a positive view on the company’s execution could see the narrative as bullish."

The price and this Narrative do not agree. → Uncover what this Narrative says Mega Lifesciences is actually worth

Find Your Own Contrarian Opportunity

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

  • Company 1 - 28% below our estimate - uses rapid payback new boutiques and rising digital sales to deepen brand reach.
  • Company 2 - 36% below our estimate - captures AI related air cargo and complex customs work with an automated freight network.
  • Company 3 - 37% below our estimate - leans on gaming and video collaboration demand after a short term supply chain shock.

Three companies from the same screener. Open every one of the 199 solid balance sheet companies →